Effects of growth hormone replacement therapy in childhood-onset craniopharyngioma: an updated systematic review and meta-analysis
Pooled result · Tumor progression/recurrenceResult — go to the resultRelative risk 0.77 95% CI 0.56–1.05Authors' conclusion
Our study suggests that GHRT does not increase the risk of tumor progression/recurrence in CP patients. GHRT can improve linear growth, but its effects on the BMI and lipid profiles remain inconclusive, requiring further studies.
Study context
- Population
- Children with childhood-onset craniopharyngioma post-surgery11 studies
- Comparison
- Growth hormone replacement therapy (GHRT) vs no GHRT
- Outcome
- Tumor progression/recurrence
Methodological detailsupdated, random-effects meta-analyses, Searched PubMed, Embase and Cochrane Library, Heterogeneity assessed using the I² statistic
- Updated
- Random-effects meta-analyses
- Searched PubMed, Embase and Cochrane Library
- Heterogeneity assessed using the I² statistic
Pooled result
As reported in the abstract
Relative risk
0.77
95% CI 0.56–1.05
P = 0.10
GHRTvs no GHRT
RR 0.77 (95% CI 0.56–1.05); P = 0.10
Further pooled results
| Outcome | MD (95% CI) | P value | |
|---|---|---|---|
| BMINo differences | −0.94 (−1.88,0.00) | P = 0.05 | |
| −2−101Difference (linear scale) |
Timing of GHRT
- Impact of timing of GHRT less clear because of limited data and high heterogeneity
Lipid profiles
- Two studies reported that GHRT might improve lipid profiles
Original publication
Effects of growth hormone replacement therapy in childhood-onset craniopharyngioma: an updated systematic review and meta-analysis. Pituitary. Published 26 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →